TITLE:

Rate of Force Development is Related to Maximal Force, Muscle Quality and Physical Function in Patients With Chronic Kidney Disease Predialysis

AUTHORS:

Jared M. Gollie, PhD, CSCS[1,2,3], Michael O. Harris-Love, PT, MPT, DSc, FGSA[4,5], Samir S. Patel, MD[6,7], Marc R. Blackman, MD[8,9,10]

AFFILIATIONS:

1. Skeletal Muscle Laboratory, Human Performance Research Unit, Clinical Research Center, Veterans Affairs Medical Center, Washington, DC 20422, USA
2. Department of Health, Human Function, and Rehabilitation Sciences, School of Medicine and Health Sciences, The George Washington University, Washington DC 20052, USA
3. Rehabilitation Science Department, College of Health and Human Services, George Mason University, Fairfax, Virginia 22030, USA
4. Department of Physical Medicine and Rehabilitation, University of Colorado School of Medicine, Aurora, Colorado 80045, USA
5. Geriatric Research Education and Clinical Center, VA Eastern Colorado Healthcare System, Aurora, Colorado 80045, USA
6. Renal Service, Veterans Affairs Medical Center, Washington, DC 20422, USA
7. Department of Medicine, School of Medicine & Health Sciences, The George Washington University, Washington DC 20052, USA
8. Laboratory of Geriatric Endocrinology and Metabolism, Veterans Affairs Medical Center, Washington, DC 20422, USA
9. Department of Medicine and Rehabilitation Medicine, School of Medicine, Georgetown University, Washington, DC 20007, USA
10. Department of Biochemistry and Molecular Medicine, School of Medicine and Health Sciences, The George Washington University, Washington DC 20037, USA

CORRESPONDING AUTHOR:

Jared M. Gollie, PhD, CSCS
jared.gollie@gmail.com
202-745-8000 ext: 55851
ORCID: 0000-0003-1066-7389

ClinicalTrials.gov NCT03160326

ABSTRACT

Physical function is severely compromised in people with chronic kidney disease (CKD) and worsens with continued decreases in kidney function. Neuromuscular force capacity is a key determinant of physical function in healthy older adults, though its importance in persons with CKD is less understood. This study aimed to determine the relationships among rate of force development (RFD), muscle quality and physical function in a group of community-dwelling, middle-aged and older men (n=14; age=71.2±6.2 years) with CKD stages 3 and 4 (eGFR=37.5±10.4 ml/min per 1.73 m^2). Force characteristics were determined from maximal knee extensor isometric contractions and muscle quality was estimated using ultrasound grayscale analysis. Physical function was assessed by the Short Physical Performance Battery (SPPB) and 5-repetition sit-to-stand (STS). eGFR was positively related to SPPB (r=0.54, p=0.044) and inversely related to STS (r=-0.62, p=0.029). RFD was positively related to SPPB at time points 0-50 ms, 50-100 ms, and 0-300 ms (RFD_{0-50}, r=0.73, p=0.010; RFD_{50-100}, r=0.67, p=0.022 and RFD_{0-300} r=0.61, p=0.045); and inversely related to STS at time points 0-50 ms, 50-100 ms, and 0-300 ms (RFD_{0-50}, r=-0.78, p=0.007; RFD_{50-100}, r=-0.78, p=0.006 and RFD_{0-300} r=-0.76, p=0.009), respectively. RFD was positively associated with maximal voluntary force (MVF) at time points 50-100 ms, 100-200 ms, and 0-300 ms (RFD_{50-100}, r=0.72, p=0.011; $RFD_{100-200}$, r=0.66, p=0.025; and RFD_{0-300} r=0.70, p=0.016). Neither MVF nor muscle quality was significantly associated with functional measures. These findings highlight the relationships between RFD and physical function in middle-aged and older men with CKD stages 3 and 4.

INTRODUCTION

Chronic kidney disease (CKD) is a progressive condition affecting an estimated 10-15% of the global population (30, 54). The physiological consequences of CKD are complex and systemic in nature, imposing deleterious effects on multiple organ systems (57). CKD is classified according to overall kidney function based on measures of estimated glomerular filtration rate (eGFR) and/or selected markers of kidney damage, such as albuminuria (54). Type II diabetes mellitus and hypertension account for the two leading causes of CKD (10, 54). Although reduced kidney function occurs as a result of the aging process, as measured by a decline in eGFR, age-related decline in kidney function it is not a cause of late stage CKD (eGFR less than 45 ml/min per 1.73 m^2) (36).

Physical function is severely compromised in people with CKD and end-stage renal disease (ESRD), and has been shown to be predictive of risk of hospitalization, disability and mortality (19, 23, 27, 28, 38, 40, 42, 45, 47, 52). For example, individuals with low functional status at the time of dialysis initiation experience a higher risk of all-cause mortality irrespective of age and history of cardiovascular disease (19). Similarly, functional measures of gait speed and timed-up-and-go are better predictors of 3-year mortality than are kidney function or commonly measured serum biomarkers in patients with CKD predialysis (46).

In healthy older adults, neuromuscular force generating capacity is a primary contributor to physical function (5, 6, 21, 43). Rate of force development (RFD) describes the rate at which force is expressed during fast and forceful contractions and has become recognized as an underlying factor contributing to physical function in older adults (17, 37). Early time intervals (i.e., <75 ms) of RFD are thought to be primarily influenced by neural factors whereas muscular factors become increasingly important with greater time from onset of contraction (32, 44). However, Gerstner et al. reported that age-associated declines in rapid torque production during

later time intervals (i.e., ≥100 ms) are influenced by alterations in muscle quality, architecture, and muscle activation.

Accelerated skeletal muscle loss is a major concern in patients with CKD and ESRD (53). Reductions in muscle cross-sectional area have been associated with declines in physical function (24, 33). Neurological complications, including peripheral neuropathy, are also highly prevalent in patients with CKD (1, 26). Accordingly, both neural and morphological alterations are potential factors contributing to muscle weakness. The loss in neuromuscular force is reported to occur more rapidly than changes in muscle cross-sectional area in patients with CKD predialysis and ESRD (25, 29). Moreover, changes in muscle cross-sectional area have been found to be poorly associated with changes in functional outcomes (25). Taken together, these observations further highlight the potential contributions of neural alterations on neuromuscular capacity in patients with CKD.

Currently there is little information describing neuromuscular contributions to physical function in patients with CKD predialysis. Consequently, the effects of compromised force characteristics and muscle quality, if present, on physical function in those with CKD predialysis are unclear. In this study, we aimed to determine the relationships among RFD, muscle quality and physical function in patients with CKD stages 3 and 4 predialysis. We hypothesized that RFD, maximal voluntary force (MVF), and muscle quality would be significantly associated with physical function in patients with CKD stages 3 and 4.

METHODS

Study Design. A single cohort, cross-sectional study design was used to examine the relationships among knee extensor RFD, maximum voluntary force (MVF), muscle quality of the rectus femoris (RF), and sit-to-stand (STS) time in a convenience sample of middle-aged and

older men with CKD stages 3 and 4 seen at a Veterans Affairs Medical Center. Data were collected by trained staff in the Renal Clinic, and Physical Medicine and Rehabilitation and Research Service groups at the Veterans Affairs Medical Center in Washington, DC (DC VAMC) and the study was registered with ClinicalTrials.gov (NCT03160326).

Participants and Ethical Approval. Community-dwelling male Veterans were screened and referred by the Renal Clinic staff at the DC VAMC for potential enrollment. The study was approved by the DC VAMC Institutional Review Board and Research and Development Committee. Inclusion criteria for study enrollment required participants to be ambulatory, with or without an assistive device, aged 18-85 years, and diagnosed with CKD stage 3 or 4, based on eGFR measures obtained within the 3-months prior to study enrollment. Exclusion criteria included a history of acute kidney injury, any uncontrolled cardiovascular or musculoskeletal problems, or having a pacemaker or implantable cardioverter defibrillator. All participants voluntarily provided written informed consent using an IRB approved form prior to study participation.

Procedures. Each participant reported to the Skeletal Muscle Laboratory in the Clinical Research Center at the DC VAMC to complete neuromuscular strength, muscle quality and physical function assessments. Participants were asked to refrain from any vigorous activity for at least 24 hours before testing. Quantitative ultrasound imaging preceded strength and functional testing. At least 30-minutes was allotted between strength and functional assessments to minimize the potential for test contamination due to fatigue.

Diagnostic Ultrasound Assessments. Methods used for diagnostic ultrasound assessments have previously been published (18, 20). Sonographic images were obtained using B-mode diagnostic ultrasound with a 5-18 MHz linear array transducer (Nobulus, Hitachi Aloka Medical,

Parsippany, NJ). Manufacturer default settings for time gain compensation and near field/far field gain were applied for all musculoskeletal scans. The field of view was adjusted for each participant to optimally capture the region of interest (ROI) of the RF on the dominant side. Water-soluble transmission gel was used during scanning to maintain adequate acoustic contact with the skin surface. Minimal examiner pressure was applied during scanning to avoid tissue deformation prior to image capture. Standardized procedures were followed for the identification of the scanning site, as previously described (18, 20). First, surface anatomy landmarks were identified at the anterior superior iliac spine and the superior pole of the patella. The bisected distance (cm) between the surface landmarks was measured using a non-elastic weighted tape measure and marked with an indelible ink pen. Quantitative ultrasound imaging was performed with the participants seated with their feet on the floor and their elbows, hips, and knees positioned at 90˚ flexion. Scanned images were obtained by a single clinical investigator (MHL) with more than 10 years of quantitative ultrasound experience.

Quantitative Strength Testing. Knee extensor strength of the dominant leg was assessed using a portable fixed dynamometer (FGV-200XY, NIDEC instruments, Itasca, IL). The dynamometer was securely mounted and anchored behind the participant. Participants were placed in the seated position on the edge of an adjustable examination table and with their hips and knees at 90˚ of flexion. A strap attached to the dynamometer was secured around the ankle of the dominant leg. Participants were allowed to use their hands for stability but were asked to refrain from grasping onto the table. A familiarization session was provided before data collection to orient each participant to the isometric testing procedures. Participants were instructed to extend or kick their leg as “hard” as possible following the test administrator’s requests, and to contract and sustain the contraction for 5-seconds while being provided strong verbal encouragement. A rest period of approximately 1-minute was provided between repetitions. Pre-

contraction tension and countermovement were removed by test administrators and the dynamometer was zeroed just before contraction initiation.

Short Physical Performance Battery (SPPB). The SPPB is a measure used to assess lower extremity function and is predictive of subsequent disability in persons over 70 years of age (15). The SPPB is composed of tasks assessing balance, walking speed, and the ability to rise from a chair. A composite score is generated with the highest possible score being 12. Those completing the respective tasks were assigned a score of 1 to 4, with higher scores representative of better performance of the task. Participants unable to complete a task were given a score of zero for that task. Complete details of the SPPB have been described elsewhere (16).

Sit-to-Stand (STS). For the purposes of this study we also examined the STS task independent of the SPPB as the ability to rise from a chair repeatedly has been used as a measure to assess lower extremity power (50). STS determined as the time taken to complete 5 sit-to-stand repetitions. Participants began by sitting quietly on a seat (height 43.2 cm) with their hands folded across their chest. If the participant was able to complete one STS repetition successfully without using his arms, he was provided the following standardized instructions for completing the test: “Please stand up straight as quickly as you can five times, without stopping in between. After standing up each time, sit down and then stand up again while keeping your arms folded across your chest.” The test was stopped if the participant became tired or short of breath, used his arms, was unable to complete the five repetitions within one-minute, or if the test administrator became concerned about the participant’s safety. Time was stopped upon the participant standing up for the fifth time indicating a successfully completed test.

Data analysis.

Quantitative Ultrasound. All scanned images were obtained and measured 3 times within the fascial borders of the muscle. The ROI selection and echogenicity measures of the RF via grayscale (GSL) histogram analysis were completed using ImageJ (version 1.48; National Institutes of Health, Bethesda, MD, USA). ROI was defined as the area within the superior and inferior fascial borders and the lateral borders of the RF. In those instances when a portion of a fascial border was poorly visualized, the examiner used the trajectory of the visible fascial border to complete the ROI selection (20). The echogenicity measures were estimated using mean GSL values within a unitless range of 0-255. This scanning procedure and imaging analysis approach has been shown to have good reliability in our facility (lower bound 95% confidence interval intraclass correlation coefficient ($ICC_{2,k}$) = 0.97-.099, $p<0.001$, standard error of measurement, SEM = 1.05 grayscale levels) (36). Subcutaneous fat was quantified according to methods described by Stock et al. (49). Briefly, ImageJ's straight-line function was used to calculate the distance between the skin-muscle interface and the superior border of the muscle's aponeurosis at three locations (left, center, right). The mean of the three thickness values from each image was utilized. GSL values were then corrected for subcutaneous fat using the following equation (49, 56): corrected GSL = uncorrected GSL + (subcutaneous fat thickness [cm] x 40.5278).

Strength Testing. The real-time force applied to the dynamometer was displayed online on a computer monitor. Force data were sampled at 100Hz and digitally stored to be analyzed offline. No more than six maximal voluntary isometric contractions were completed during strength assessments. Peak isometric knee extensor strength was determined by averaging 3 attempts which fell within 10% of each other or the 3 highest values of the six attempts. Rate of force development (RFD) was calculated as the change in force by change in time following the initiation of isometric knee extension contraction and assessed over consecutive time epochs; 0-50 ms, 50-100 ms, 100-200 ms, and 200-300 ms (i.e., RFD_{0-50}, RFD_{50-100}, $RFD_{100-200}$, and

$RFD_{200-300}$). RFD was also calculated as the change in force by the change in time over the first 300 ms of the contraction (i.e., RFD_{0-300}) (**Figure 1**). The onset of contraction was determined as the first derivative of the filtered force signaling that crossed 2.5% of peak force (32). In addition to absolute RFD, RFD is expressed relative to MVF (RFD/MVF), corrected RF GSL (RFD/GSL), and RF muscle thickness (MT) (RFD/MT) (31, 32, 44). Specific force was calculated as MVF divided by RF MT and absolute MVF was normalized to body mass (BM) to power two-thirds ($N/kg^{0.67}$) (22).

[insert Fig. 1]

Statistical analyses.

Data are presented as mean values ± SD unless otherwise noted. Normality of each variable was assessed with the Shapiro-Wilk test. Pearson product-moment correlation coefficients (r) were used to determine associations among estimates of knee extensor strength, muscle quality, and physical function. The magnitudes of the correlation coefficients were described as 0.00-0.30, 0.30-0.50, 0.50-0.70, 0.70-0.90, and 0.90-1.00 and interpreted as negligible, low, moderate, high, and very high, respectively (35). Statistical significance was set at $p<0.05$ for two-tailed tests. Statistical analyses were performed using SPSS version 26 (SPSS Inc., Chicago, IL).

RESULTS

Participant characteristics are presented in **Table 1**. Study participants were classified as exhibiting moderately to severely decreased kidney function based on mean eGFR, with 14% of participants classified with CKD stage 3a (n=2), 57% with CKD stage 3b (n=8), and 29% with CKD stage 4 (n=4). According to BMI, 36% of participants were classified as overweight (n=5) while 64% were classified as obese (n=9). Two of the fourteen participants, both classified as

CKD stage 4, were unable to complete a single STS repetition and therefore were not included in the STS analysis. eGFR was positively related to the SPPB (r=0.54, p=0.044) and inversely related to STS (r=-0.62, p=0.029). No other significant relationships were observed between eGFR and RFD outcomes, MVF, RF GSL, or RF MT (data not shown). RFD data were unavailable on three participants; and therefore, eleven participants were included in the analysis of the relationships between function and muscle-specific outcomes with RFD unless otherwise noted. Of the three participants without RFD data, one was not able to complete the STS task.

[insert Table 1]

Short Physical Performance Battery (SPPB)

Participant RFD estimations are displayed in **Table 2**. **Figure 2** shows the relationships between the SPPB and RFD. SPPB was positively associated with RFD at time points 0-50 ms, 50-100 ms, and 0-300 ms (RFD_{0-50}, r=0.73, p=0.010; RFD_{50-100}, r=0.67, p=0.022 and RFD_{0-300} r=0.61, p=0.045); and with RFD/GSL at time points 0-50 ms, 50-100 ms, and 0-300 ms (RFD/GSL_{0-50}, r=0.70, p=0.015; RFD/GSL_{50-100}, r=0.76, p=0.006 and RFD/GSL_{0-300} r=0.63, p=0.035), respectively. The SPPB was not significantly related to MVF, RF GLS, corrected RF GSL, RF MT, or specific force (data not shown).

[insert Table 2]

[insert Fig. 2]

Sit-to-Stand (STS)

Ten participants are included in the analysis of the relationship between STS and RFD due to two participants being unable to perform the STS assessment and the absence of RFD on three participants (**Figure 3**). The STS was inversely associated with RFD at time points 0-50 ms, 50-100 ms, and 0-300 ms (RFD_{0-50}, r=-0.78, p=0.007; RFD_{50-100}, r=-0.78, p=0.006 and RFD_{0-300} r=-0.76, p=0.009) and with RFD/MVF at time points 0-50 ms, 50-100 ms, and 0-300 ms (RFD/MVF_{0-50}, r=-0.67, p=0.033; RFD/MVF_{50-100}, r=-0.80, p=0.005 and RFD/MVF_{0-300} r=-0.73, p=0.015), respectively. The STS was also inversely related to RFD/GSL at time points 0-50 ms, 50-100 ms, and 0-300 ms (RFD/GSL_{0-50}, r=-0.71, p=0.021; RFD/GSL_{50-100}, r=-0.78, p=0.008 and RFD/GSL_{0-300} r=-0.64, p=0.042; respectively) and RFD/MT at time point 0-50 ms (RFD/MT_{0-50}, r=-0.66, p=0.034), respectively. The STS was not significantly related to MVF, RF GSL, corrected RF GSL, RF MT, or specific force (data not shown).

[insert Fig. 3]

Maximal Voluntary Force (MVF)

Figure 4 shows the relationships between the MVF and RFD. MVF was positively related to RFD at time points 50-100 ms, 100-200 ms, and 0-300 ms (RFD_{50-100}, r=0.72, p=0.011; $RFD_{100-200}$, r=0.66, p=0.025; and RFD_{0-300} r=0.70, p=0.016); and to RFD/GSL at time points 50-100 ms and 100-200 ms (RFD/GSL_{50-100}, r=0.71, p=0.014 and $RFD/GSL_{100-200}$, r=0.62, p=0.039) respectively; but not to RFD/MT (data not shown). Normalized MVF was positively related to RFD/GSL at time points 50-100 ms, 100-200 ms, and 0-300 (RFD/GSL_{50-100}, r=0.61, p=0.042; $RFD/GSL_{100-200}$, r=0.62, p=0.039; and to RFD/GSL_{0-300}, r=0.64, p=0.034; respectively).

[insert Fig. 4]

Muscle Quality

Corrected RF GSL was inversely associated with RFD/MVF at time point 0-300 ($RFD/MVF_{0\text{-}300}$, r=-0.60; p=0.049) (*data not shown*).

Specific Force

Specific force was positively associated with RFD at time point 100-200 ms ($RFD_{100\text{-}200}$, r=0.67, p=0.022); and with RFD/GSL at time point 100-200 ms ($RFD/GSL_{100\text{-}200}$, r=0.60, p=0.050) (*data not shown*).

DISCUSSION

This study assessed the associations between functional performance (i.e., SPPB and STS) and selected muscle-specific outcomes in a group of community-dwelling, middle-aged and older men with CKD stages 3 & 4 predialysis. Reduced kidney function, as assessed by eGFR, was associated with declines in functional assessments. Moderate to strong relationships were found between RFD and SPPB, STS, and MVF. When controlling for MVF, RFD was moderately to strongly association with STS and moderately related to muscle quality. While RFD was associated with MVF, no significant relationships were observed between measures of MVF and functional outcomes. Thus, the findings of the present study suggest that functional performance is significantly related to RFD in middle aged and older men with CKD stages 3 and 4 predialysis.

Functional changes with aging have been shown to be strongly associated with lower extremity force characteristics, in particular, with neuromuscular power and RFD (41, 43). For example, neuromuscular power generated during the STS task relates to functional performance measures across a variety of domains (strength, endurance, speed, and agility), even in the presence of sarcopenia (13). The decline in physical function is accelerated in patients with CKD predialysis and ESRD and progressively worsens as kidney function declines (9, 27, 33). Variations of the STS task have been found to be related to aerobic capacity and muscle cross-sectional area in patients with CKD predialysis and ESRD (33, 38). The current results are in agreement with previous findings on STS and CKD in demonstrating an inverse moderate relationship between eGFR and STS. The present data extend previous findings, showing inverse, moderate-to-high associations between RFD at time points 0-50 ms, 50-100 ms, and 0-300 ms, and the STS. Moreover, the relationship between RFD and STS was maintained when controlling for maximal force (i.e., MVF) and muscle quality (i.e., RF GSL).

Evidence also suggests the presence of neurological alterations in early stages of CKD prior to dialysis initiation, even in the absence of objective clinical signs (1, 3, 51). Such neurological abnormalities, if present, are likely to impact RFD. For example, impaired potassium homeostasis is commonly reported in patients with ESRD and found to alter nerve function and morphology (4, 8). Limited data is currently available impact of CKD and ESRD on RFD. Molsted et al. reported that 16-weeks of resistance exercise increased electromyographic (EMG) amplitude during the 200-300 ms time period following the onset of muscle contraction in dialysis patients with a concomitant increase of 21-38% in RFD of the knee extensors (34). These findings support resistance exercise as a possible treatment option for enhancing RFD in patients with ESRD. The results of the present study extend these findings demonstrating a positive linear relationship between functional performance RFD in patients with CKD stages 3 and 4.

The ability to produce high levels of force rapidly is predictive of functional performance. While peak knee extensor force (i.e., MVF) was not related to functional ability in the current study, it was positively associated with absolute RFD at time points 50-100 ms, 100-200 ms, and 0-300 ms, suggesting that peak isometric knee extensor force has important implications for RFD in adults with CKD predialysis. It has been suggested that voluntary RFD becomes increasingly more dependent on maximal force generating capacity and less dependent on muscle twitch characteristics with increasing time after the onset of contraction (2). At time intervals later than 90 ms from the onset of contraction, maximal strength accounted for 52-81% of the variance in RFD. In contrast, in very early time intervals (< 40 ms), RFD was moderately associated with twitch contractile properties and less related to maximal force capacity (2).

Research on neuromuscular properties in patients with kidney disease has primarily focused on muscle size in the ESRD population on dialysis due to their increased risk for accelerated muscle loss (53). Johansen et al. demonstrated that decreased gait speed was associated with loss in muscle contractile area and maximal isometric knee extensor strength in ambulatory hemodialysis participants (24). However, the authors found no evidence of reduced muscle quality as determined by the ratio of muscle strength to contractile cross-sectional area (24). John et al. followed a cohort of stage 4 and 5 CKD predialysis, hemodialysis, and peritoneal dialysis patients for 2-years and found change in muscle cross-sectional area was poorly correlated with 5-repetition STS (25). In non-dialysis patients, Wilkinson et al. found that muscle quality, as determined by RF echo-intensity, was inversely related to 60-second STS, incremental shuttle walk test, and VO_2peak; but that RF cross-sectional area was a better predictor of physical performance when compared to muscle quality (55). The lack of consistency among the relationships between physical function and neuromuscular outcomes

underscores the complexity of CKD and ESRD. Our results posit RFD as an additional variable to aid in the understanding of CKD predialysis on physical function and neuromuscular capacity.

Clinical Implications. Resistance exercise has been reported to increase both strength (+18% to +33%) and RFD (+27%) in older adults (7, 39, 48). To date, resistance exercise in CKD patients predialysis has been relatively under studied when compared to investigations of aerobic exercise and exercise in generally healthy older adults. Several systematic reviews and meta-analyses have reported improvements in neuromuscular strength and lower extremity muscle cross-sectional area after progressive resistance exercise in patients with CKD predialysis and ESRD (11, 12). Recently, Gollie et al. highlighted the relative lack of information on the effects of resistance exercise for improving neuromuscular power in patients with CKD predialysis and proposed a conceptual framework for targeting specific neuromuscular outcomes through the manipulation of resistance exercise variables (14). Future studies are warranted to determine which resistance exercise variables are critical for enhancing force characteristics and physical function in patients with CKD predialysis.

Limitations. The small sample size and lack of women participants precludes generalization of the current findings beyond our study sample. The absence of control study participants, i.e. individuals without moderate to severe declines in kidney function, limits the ability to determine if, or the extent to which, RFD was compromised because of CKD in our patient population. The instructions in the present study to contract as “hard” as possible may have resulted in an underestimation of the RFD capabilities of our study participants. Lastly, the presence of multiple comorbidities is common in patients with CKD predialysis; consequently, it is unclear how the type and number of comorbidities in our study population may have influenced the findings of the current study.

Conclusions

In community-dwelling, middle-aged and older men with CKD stages 3 and 4, RFD is significantly associated with MVF, muscle quality and physical function. Further studies are warranted to determine the responsiveness of RFD to exercise interventions targeting physical function in patients with CKD predialysis and ESRD.

Acknowledgements

This study was conducted as part of a VA funded Center of Innovation award (VACI# AM-251) between the San Francisco VAMC and the Washington D.C. VAMC, the aim of which was to investigate clinically viable approaches for the assessment of sarcopenia in Veterans with CKD stages 3 and4 predialysis (ClinicalTrials.gov NCT03160326).

References

1. **Aggarwal HK**, **Sood S**, **Jain D**, **Kaverappa V**, **Yadav S**. Evaluation of spectrum of peripheral neuropathy in predialysis patients with chronic kidney disease. *Ren Fail* 35: 1323–1329, 2013.

2. **Andersen LL**, **Aagaard P**. Influence of maximal muscle strength and intrinsic muscle contractile properties on contractile rate of force development. *Eur J Appl Physiol* 96: 46–52, 2006.

3. **Arnold R**, **Pianta TJ**, **Pussell BA**, **Endre Z**, **Kiernan MC**, **Krishnan AV**. Potassium control in chronic kidney disease: Implications for neuromuscular function. *Intern. Med. J.*, 2018.

4. **Arnold R**, **Pussell BA**, **Howells J**, **Grinius V**, **Kiernan MC**, **Lin CS-Y**, **Krishnan AV**. Evidence for a causal relationship between hyperkalaemia and axonal dysfunction in end-stage kidney disease. *Clin Neurophysiol* 125: 179–185, 2014.

5. **Bassey EJ**, **Fiatarone MA**, **O'Neill EF**, **Kelly M**, **Evans WJ**, **Lipsitz LA**. Leg extensor power and functional performance in very old men and women. *Clin Sci Lond Engl 1979* 82: 321–327, 1992.

6. **Bean JF**, **Leveille SG**, **Kiely DK**, **Bandinelli S**, **Guralnik JM**, **Ferrucci L**. A comparison of leg power and leg strength within the InCHIANTI study: which influences mobility more? *J Gerontol A Biol Sci Med Sci* 58: 728–733, 2003.

7. **Borde R**, **Hortobágyi T**, **Granacher U**. Dose–Response Relationships of Resistance Training in Healthy Old Adults: A Systematic Review and Meta-Analysis. *Sports Med* 45: 1693–1720, 2015.

8. **Borire AA**, **Arnold R**, **Pussell BA**, **Kwai NC**, **Visser LH**, **Padua L**, **Simon NG**, **Kiernan MC**, **Krishnan AV**. Haemodialysis alters peripheral nerve morphology in end-stage kidney disease. *Clin Neurophysiol* 128: 281–286, 2017.

9. **Brodin E**, **Ljungman S**, **Stibrant Sunnerhagen K**. Rising from a chair A simple screening test for physical function in predialysis patients. *Scand J Urol Nephrol* 42: 293–300, 2008.

10. **Centers for Disease Control and Prevention**. *Chronic Kidney Disease in the United States, 2019*. US Department of Health and Human Services, Centers for Disease Control and Prevention, 2019.

11. **Chan D**, **Cheema BS**. Progressive Resistance Training in End-Stage Renal Disease: Systematic Review. *Am J Nephrol* 44: 32–45, 2016.

12. **Cheema BS**, **Chan D**, **Fahey P**, **Atlantis E**. Effect of Progressive Resistance Training on Measures of Skeletal Muscle Hypertrophy, Muscular Strength and Health-Related Quality of Life in Patients with Chronic Kidney Disease: A Systematic Review and Meta-Analysis. *Sports Med* 44: 1125–1138, 2014.

13. **Glenn JM**, **Gray M**, **Binns A**. Relationship of Sit-to-Stand Lower-Body Power With Functional Fitness Measures Among Older Adults With and Without Sarcopenia: *J Geriatr Phys Ther* 40: 42–50, 2017.

14. **Gollie JM**, **Harris-Love MO**, **Patel SS**, **Argani S**. Chronic kidney disease: considerations for monitoring skeletal muscle health and prescribing resistance exercise. *Clin Kidney J* 11: 822–831, 2018.

15. **Guralnik JM**, **Ferrucci L**, **Simonsick EM**, **Salive ME**, **Wallace RB**. Lower-extremity function in persons over the age of 70 years as a predictor of subsequent disability. *N Engl J Med* 332: 556–561, 1995.

16. **Guralnik JM**, **Simonsick EM**, **Ferrucci L**, **Glynn RJ**, **Berkman LF**, **Blazer DG**, **Scherr PA**, **Wallace RB**. A Short Physical Performance Battery Assessing Lower Extremity Function: Association With Self-Reported Disability and Prediction of Mortality and Nursing Home Admission. *J Gerontol* 49: M85–M94, 1994.

17. **Haff GG**, **Nimphius S**. Training Principles for Power. *Strength Cond J* 34: 2–12, 2012.

18. **Harris-Love MO**, **Gonzales TI**, **Wei Q**, **Ismail C**, **Zabal J**, **Woletz P**, **DiPietro L**, **Blackman MR**. Association Between Muscle Strength and Modeling Estimates of Muscle Tissue Heterogeneity in Young and Old Adults. *J. Ultrasound Med.*, 38: 1757-1768, 2018.

19. **Inaguma D**, **Tanaka A**, **Shinjo H**. Physical function at the time of dialysis initiation is associated with subsequent mortality. *Clin Exp Nephrol* 21: 425–435, 2017.

20. **Ismail C**, **Zabal J**, **Hernandez HJ**, **Woletz P**, **Manning H**, **Teixeira C**, **DiPietro L**, **Blackman MR**, **Harris-Love MO**. Diagnostic Ultrasound Estimates of Muscle Mass and Muscle Quality Discriminate Between Women With and Without Sarcopenia. *Front Physiol* 6, 2015.

21. **Izquierdo M**, **Aguado X**, **Gonzalez R**, **López JL**, **Häkkinen K**. Maximal and explosive force production capacity and balance performance in men of different ages. *Eur J Appl Physiol* 79: 260–267, 1999.

22. **Jaric S**. Muscle Strength Testing: Use of Normalisation for Body Size. *Sports Med* 32: 615–631, 2002.

23. **Johansen KL**, **Chertow GM**, **Da Silva M**, **Carey S**, **Painter P**. Determinants of physical performance in ambulatory patients on hemodialysis. *Kidney Int* 60: 1586–1591, 2001.

24. **Johansen KL**, **Shubert T**, **Doyle J**, **Soher B**, **Sakkas GK**, **Kent-Braun JA**. Muscle atrophy in patients receiving hemodialysis: effects on muscle strength, muscle quality, and physical function. *Kidney Int* 63: 291–297, 2003.

25. **John SG**, **Sigrist MK**, **Taal MW**, **McIntyre CW**. Natural History of Skeletal Muscle Mass Changes in Chronic Kidney Disease Stage 4 and 5 Patients: An Observational Study. *PLoS ONE* 8: e65372, 2013.

26. **Krishnan AV**, **Kiernan MC**. Neurological complications of chronic kidney disease. *Nat Rev Neurol* 5: 542–551, 2009.

27. **Kurella Tamura M**, **Covinsky KE**, **Chertow GM**, **Yaffe K**, **Landefeld CS**, **McCulloch CE**. Functional Status of Elderly Adults Before and After Initiation of Dialysis. *N Engl J Med* 361: 1539–1547, 2009.

28. **Kutner NG**, **Zhang R**, **Huang Y**, **Painter P**. Gait Speed and Mortality, Hospitalization, and Functional Status Change Among Hemodialysis Patients: A US Renal Data System Special Study. *Am J Kidney Dis Off J Natl Kidney Found* 66: 297–304, 2015.

29. **Leikis MJ**. Exercise Performance Falls over Time in Patients with Chronic Kidney Disease Despite Maintenance of Hemoglobin Concentration. *Clin J Am Soc Nephrol* 1: 488–495, 2006.

30. **Levin A**, **Tonelli M**, **Bonventre J**, **Coresh J**, **Donner J-A**, **Fogo AB**, **Fox CS**, **Gansevoort RT**, **Heerspink HJL**, **Jardine M**, **Kasiske B**, **Köttgen A**, **Kretzler M**, **Levey AS**, **Luyckx VA**, **Mehta R**, **Moe O**, **Obrador G**, **Pannu N**, **Parikh CR**, **Perkovic V**, **Pollock C**, **Stenvinkel P**, **Tuttle KR**, **Wheeler DC**, **Eckardt K-U**, **Adu D**, **Agarwal SK**, **Alrukhaimi M**, **Anders H-J**, **Ashuntantang G**, **Basnet S**, **Bello AK**, **Chailimpamontree W**, **Correa-Rotter R**, **Craig J**, **Douthat WG**, **Feldman HI**, **Ganji MR**, **Garcia-Garcia G**, **Gharbi MB**, **Harris DC**, **Jha V**, **Johnson DW**, **Kazancioglu R**, **Langham R**, **Liu Z-H**, **Massy ZA**, **Nangaku M**, **Nelson RG**, **O'Donoghue D**, **Okpechi I**, **Pecoits-Filho R**, **Powe NR**, **Remuzzi G**, **Roberts C**, **Rossert J**, **Sola L**, **Stengel B**, **M EKS**, **Suzuki Y**, **Tanaka T**, **Tatiyanupanwong S**, **Thomas B**, **Uhlig K**, **Walker R**, **White SL**, **Wiecek A**, **Yang C-W**. Global Kidney Health 2017 and Beyond: A Roadmap for Closing Gaps in Care, Research, and Policy. *The Lancet*. 2017.

31. **Lopez P**, **Wilhelm EN**, **Rech A**, **Minozzo F**, **Radaelli R**, **Pinto RS**. Echo intensity independently predicts functionality in sedentary older men: Muscle Echo Intensity in Older Men. *Muscle Nerve* 55: 9–15, 2017.

32. **Maffiuletti NA**, **Aagaard P**, **Blazevich AJ**, **Folland J**, **Tillin N**, **Duchateau J**. Rate of force development: physiological and methodological considerations. *Eur J Appl Physiol* 116: 1091–1116, 2016.

33. **McIntyre CW**, **Selby NM**, **Sigrist M**, **Pearce LE**, **Mercer TH**, **Naish PF**. Patients receiving maintenance dialysis have more severe functionally significant skeletal muscle wasting than patients with dialysis-independent chronic kidney disease. *Nephrol Dial Transplant Off Publ Eur Dial Transpl Assoc - Eur Ren Assoc* 21: 2210–2216, 2006.

34. **Molsted S**, **Andersen JL**, **Eidemak I**, **Harrison AP**. Increased rate of force development and neuromuscular activity after high-load resistance training in patients undergoing dialysis: Force development and training in dialysis patients. *Nephrology* 18: 770–776, 2013.

35. **Mukaka MM**. Statistics corner: A guide to appropriate use of correlation coefficient in medical research. *Malawi Med J J Med Assoc Malawi* 24: 69–71, 2012.

36. **O'Hare AM**, **Choi AI**, **Bertenthal D**, **Bacchetti P**, **Garg AX**, **Kaufman JS**, **Walter LC**, **Mehta KM**, **Steinman MA**, **Allon M**, **McClellan WM**, **Landefeld CS**. Age Affects Outcomes in Chronic Kidney Disease. *J Am Soc Nephrol* 18: 2758–2765, 2007.

37. **Osawa Y**, **Studenski SA**, **Ferrucci L**. Knee extension rate of torque development and peak torque: associations with lower extremity function: Rate of torque development and lower extremity function. *J Cachexia Sarcopenia Muscle* 9: 530–539, 2018.

38. **Padilla J**, **Krasnoff J**, **Da Silva M**, **Hsu C-Y**, **Frassetto L**, **Johansen KL**, **Painter P**. Physical functioning in patients with chronic kidney disease. *J Nephrol* 21: 550–559, 2008.

39. **Peterson MD**, **Rhea MR**, **Sen A**, **Gordon PM**. Resistance exercise for muscular strength in older adults: A meta-analysis. *Ageing Res Rev* 9: 226–237, 2010.

40. **Plantinga LC**, **Johansen K**, **Crews DC**, **Shahinian VB**, **Robinson BM**, **Saran R**, **Burrows NR**, **Williams DE**, **Powe NR**. Association of CKD With Disability in the United States. *Am J Kidney Dis* 57: 212–227, 2011.

41. **Puthoff ML**, **Nielsen DH**. Relationships among impairments in lower-extremity strength and power, functional limitations, and disability in older adults. *Phys Ther* 87: 1334–1347, 2007.

42. **Reese PP**, **Cappola AR**, **Shults J**, **Townsend RR**, **Gadegbeku CA**, **Anderson C**, **Baker JF**, **Carlow D**, **Sulik MJ**, **Lo JC**, **Go AS**, **Ky B**, **Mariani L**, **Feldman HI**, **Leonard MB**, **CRIC Study Investigators**. Physical Performance and Frailty in Chronic Kidney Disease. *Am J Nephrol* 38: 307–315, 2013.

43. **Reid KF**, **Fielding RA**. Skeletal muscle power: a critical determinant of physical functioning in older adults. *Exerc Sport Sci Rev* 40: 4–12, 2012.

44. **Rodríguez-Rosell D**, **Pareja-Blanco F**, **Aagaard P**, **González-Badillo JJ**. Physiological and methodological aspects of rate of force development assessment in human skeletal muscle. *Clin Physiol Funct Imaging* 38: 743–762, 2018.

45. **Roshanravan B**, **Patel KV**. Assessment of physical functioning in the clinical care of the patient with advanced kidney disease. *Semin Dial* 32: 351–360, 2019.

46. **Roshanravan B**, **Robinson-Cohen C**, **Patel KV**, **Ayers E**, **Littman AJ**, **de Boer IH**, **Ikizler TA**, **Himmelfarb J**, **Katzel LI**, **Kestenbaum B**, **Seliger S**. Association between Physical Performance and All-Cause Mortality in CKD. *J Am Soc Nephrol* 24: 822–830, 2013.

47. **Sietsema KE**, **Amato A**, **Adler SG**, **Brass EP**. Exercise capacity as a predictor of survival among ambulatory patients with end-stage renal disease. *Kidney Int* 65: 719–724, 2004.

48. **Stewart VH**, **Saunders DH**, **Greig CA**. Responsiveness of muscle size and strength to physical training in very elderly people: A systematic review: Hypertrophic ability of older muscle. *Scand J Med Sci Sports* 24: e1–e10, 2014.

49. **Stock MS**, **Whitson M**, **Burton AM**, **Dawson NT**, **Sobolewski EJ**, **Thompson BJ**. Echo Intensity Versus Muscle Function Correlations in Older Adults are Influenced by Subcutaneous Fat Thickness. *Ultrasound Med Biol* 44: 1597–1605, 2018.

50. **Takai Y**, **Ohta M**, **Akagi R**, **Kanehisa H**, **Kawakami Y**, **Fukunaga T**. Sit-to-stand Test to Evaluate Knee Extensor Muscle Size and Strength in the Elderly: A Novel Approach. *J Physiol Anthropol* 28: 123–128, 2009.

51. **Tilki HE**, **Akpolat T**, **Coşkun M**, **Stålberg E**. Clinical and electrophysiologic findings in dialysis patients. *J Electromyogr Kinesiol* 19: 500–508, 2009.

52. **van Loon I**, **Hamaker ME**, **Boereboom FTJ**, **Grooteman MPC**, **Blankestijn PJ**, **van den Dorpel RMA**, **Nubé MJ**, **Ter Wee PM**, **Verhaar MC**, **Bots ML**. A closer look at the trajectory of physical functioning in chronic hemodialysis. *Age Ageing* 46: 594–599, 2017.

53. **Wang XH**, **Mitch WE**. Mechanisms of Muscle Wasting in Chronic Kidney Disease. *Nat Rev Nephrol* 10: 504–516, 2014.

54. **Webster AC**, **Nagler EV**, **Morton RL**, **Masson P**. Chronic Kidney Disease. *The Lancet* 389: 1238–1252, 2017.

55. **Wilkinson TJ**, **Gould DW**, **Nixon DGD**, **Watson EL**, **Smith AC**. Quality over quantity? Association of skeletal muscle myosteatosis and myofibrosis on physical function in chronic kidney disease. *Nephrol. Dial. Transplant. Off. Publ. Eur. Dial. Transpl. Assoc. - Eur. Ren. Assoc.*, 2018.

56. **Young H-J**, **Jenkins NT**, **Zhao Q**, **Mccully KK**. Measurement of intramuscular fat by muscle echo intensity: Muscle Echo Intensity and Fat. *Muscle Nerve* 52: 963–971, 2015.

57. **Zoccali C**, **Vanholder R**, **Massy ZA**, **Ortiz A**, **Sarafidis P**, **Dekker FW**, **Fliser D**, **Fouque D**, **Heine GH**, **Jager KJ**, **Kanbay M**, **Mallamaci F**, **Parati G**, **Rossignol P**, **Wiecek A**, **London G**. The systemic nature of CKD. *Nat Rev Nephrol* 13: 344–358, 2017.

Figure Legend

Figure 1. Example of a force-time curve during maximal voluntary isometric contraction of the dominant knee extensor depicting the specific time intervals used for assessment. *N*, newton; *ms*, millisecond

Figure 2. Relationship between SPPB and RFD at time intervals 0-50ms (a), 50-100 ms (b), and 0-300 ms (c); and the relationship between SPPB and RFD normalized to corrected RF GSL at time intervals 0-50 ms (d), 50-100 ms (e), and 0-300 ms (f). *RFD*, rate of force development; *GSL*, corrected rectus femoris grayscale; *SPPB*, Short Physical Performance Battery; *N*, Newton; *s*, second; *a.u.*, arbitrary unit.

Figure 3. Relationship between STS and RFD at time intervals 0-50 ms (a), 50-100 ms (b), and 0-300 ms (c); the relationship between STS and RFD/MVF at time intervals 0-50 ms (d), 50-100 ms (e), and 0-300 ms (f); and the relationship between STS and RFD/GSL at time intervals 0-50 ms (g), 50-100 ms (h), and 0-300 ms (i). *RFD*, rate of force development; *MVF*, maximal voluntary force; *GSL*, corrected rectus femoris grayscale; *STS*, Sit-to-Stand; *N*, Newton; *s*, second; *a.u.*, arbitrary unit.

Figure 4. Relationship between RFD and MVF at time intervals 50-100 ms (a), 100-200 ms (b), and 0-300 ms (c); the relationship between RFD/GSL and MVF at time intervals 50-100 ms (d) and 100-200 ms; and the relationship between RFD/GSL and Normalized MVF at time intervals 50-100 ms (f), 100-200 ms (g), and 0-300 ms (h). *RFD*, rate of force development; *GSL*, corrected rectus femoris grayscale; *MVF*, maximal voluntary force. *N*, Newton; *kg*, kilogram; *s*, second; *a.u.*, arbitrary unit.

Table 1. Participant characteristics (n=14).

Outcome	mean (SD)
Age (years)	71.2 (6.2)
Height (cm)	175.1 (7.3)
Weight (kg)	103.1 (22.1)
BMI (kg/m^2)	33.5 (5.9)
eGFR (mL/min per 1.73 m^2)	37.5 (10.4)
Potassium (mmol/L)	4.7 (0.6)
SPPB	8.6 (2.4)
STS (s)	14.8 (3.3)
MVF (N)	371 (78.8)
Normalized MVF (N/kg$^{0.67}$)	16.9 (3.7)
Specific force (N/cm)	16.2 (5.1)
RF GSL (a.u.)	80.4 (10.8)
Corrected RF GSL (a.u.)	132.7 (19.7)
RF MT (cm)	23.9 (5.0)
Subcutaneous fat tissue (cm)	1.3 (0.5)

**n=11 for sit-to-stand (STS) task*.

Abbreviations. *eGFR*, estimated glomerular filtration rate; *cm*, centimeters; *kg*, kilogram; *m*, meter; *mg*, milligram; *dl*, deciliter; *g*, gram; *%*, percent; *SPPB*, Short Physical Performance Battery; *STS*, sit-to-stand; *s*, seconds; *MVF*, maximal voluntary force; *N*, Newton; *RF GSL*, rectus femoris grayscale; *a.u.*, arbitrary units; *RF MT*, rectus femoris muscle thickness

Table 2. Absolute and relative rate of force development (RFD) estimations in male Veterans with CKD stages 3 and 4 (n=11).

Outcome	0-50ms	50-100 ms	100-200 ms	200-300 ms	0-300 ms
RFD (N·s)	1334.7 (713.9)	988.2 (334.9)	727.9 (371.9)	382.5 (226.5)	874.8 (272.2)
RFD/MVF (N·s·N)	3.5 (1.8)	2.5 (0.6)	1.8 (0.8)	1.0 (0.7)	2.2 (0.5)
RFD/GSL (N·s·a.u.)	10.7 (6.8)	7.7 (2.9)	5.8 (3.4)	2.9 (1.8)	6.9 (2.8)
RFD/MT (N·s·cm)	58.0 (35.9)	43.4 (17.3)	33.5 (21.8)	17.3 (12.6)	39.1 (16.5)

Data presented as mean values (SD).

Abbreviations. *RFD*, rate of force development; *RFD/MVF*, rate of force development normalized to maximal voluntary force; *RFD/GLS*, rate of force development normalized to corrected rectus femoris grayscale; *RFD/MT*, rate of force development normalized to rectus femoris muscle thickness; *N*, Newton; *s*, second; *a.u.*, arbitrary unit; *cm*, centimeter.

Figure 1


300
250
200
150
100
50
0
RFD (N)
0-50 ms
50-100 ms
100-200 ms
200-300 ms
0-300 ms
0
10
20
30
40
50
60
70
80
100
110
120
130
140
150
160
170
180
190
200
210
220
230
240
250
260
270
280
290
300
Time (ms)

Figure 2


a.
b.
c.
d.
e.
f.
RFD0-50 (N·s)
RFD50-100 (N·s)
RFD0-300 (N·s)
RFD/GSL0-50 (N·s·a.u.)
RFD/GSL50-100 (N·s·a.u.)
RFD/GSL0-300 (N·s·a.u.)
SPPB

Figure 3


a.
RFD0-50 (N·s)
STS (s)
b.
RFD50-100 (N·s)
STS (s)
c.
RFD0-300 (N·s)
STS (s)
d.
RFD/MVF0-50 (N·s·N)
STS (s)
e.
RFD/MVF50-100 (N·s·N)
STS (s)
f.
RFD/MVF0-300 (N·s·N)
STS (s)
g.
RFD/GSL0-50 (N·s·a.u.)
STS (s)
h.
RFD/GSL50-100 (N·s·a.u.)
STS (s)
i.
RFD/GSL0-300 (N·s·a.u.)
STS (s)

Figure 4


a.
RFD50-100 (N·s)
MVF (N)
b.
RFD100-200 (N·s)
MVF (N)
c.
RFD0-300 (N·s)
MVF (N)
d.
RFD/GSL50-100 (N·s·a.u.)
MVF (N)
e.
RFD/GSL100-200 (N·s·a.u.)
MVF (N)
f.
RFD/GSL50-100 (N·s·a.u.)
Normalized MVF (N·kg-.67)
g.
RFD/GSL100-200 (N·s·a.u.)
Normalized MVF (N·kg-.67)
h.
RFD/GSL0-300 (N·s·a.u.)
Normalized MVF (N·kg-.67)